본문바로가기
  • ABOUT US
  • Overview

ABOUT US

Diversified pharmaceutical company with divisions
for novel medicines and complex generics

ArborMed is a biopharmaceutical company committed to the development and commercialization of therapeutics for diseases with high unmet medical needs and untapped market opportunities.

With operations in South Korea and US, Arbormed utilizes resources efficiently to enable "Fast to Market" development of the pipeline and US market entry.

Our Demand-Driven Development (D3) approach incorporates 3 strategic pillars to build a risk-balanced pipeline:

Innovative new drug - starting from mid preclinical stage, develop best in class therapies with validated targets with a particular focus on rare diseases.

Biobetter or IMD(Incrementally Modified Drug) - starting from late preclinical to early clinical stage, develop differentiated versions of FDA approved products with potential for significant clinical benefit compared to the original drug.

Complex generics - commercialize complex generic products with limited competition in the US that have been developed by Korean companies.

ARBORMED Co., Ltd.

Parent Company Innovative Drug Development
Location Seoul, South Korea
Establish Dec. 2017
Pipelines 3 innovative assets ARBM-101, Wilson’s disease therapy Ropivacaine ER Enbrel Biobetter
IPO KOSDAQ in Korea 2023~2024

ARBORMED Pharmaceuticals Inc.

Subsidiary(Wholly Owned) US Medicine licensed distributor
Location San Francisco, CA, USA
Establish April 2016
Pipelines Acquired 7 complex generic products Oncology injections from Korea United Patch products from Icure Peptide injections from Penmix
FDA approval & launching 2023~2024